Navigation Links
Avanir Pharmaceuticals Announces Positive Results of Phase III,Study for Zenvia in Diabetic Neuropathic Pain

and approved by the U.S. Food and Drug Administration (FDA) through a special protocol assessment (SPA). The Company expects this to be the first of two pivotal studies required for the approval of Zenvia in the treatment of diabetic neuropathic pain.

About Zenvia

Zenvia is a combination of two well-characterized compounds, the active ingredient dextromethorphan, and the enzyme inhibitor quinidine, which serves to increase the bioavailability of dextromethorphan. The first-in-class drug candidate is believed to help regulate excitatory neurotransmission in two ways, through pre-synaptic inhibition of glutamate release via sigma-1 receptor agonist activity, and through postsynaptic glutamate response modulation via uncompetitive, low-affinity NMDA antagonist activity. Zenvia is currently in development for the treatment of Involuntary Emotional Expression Disorder (IEED) and diabetic neuropathic pain.

In October 2006, the Company received an approvable letter for the treatment of Zenvia in IEED. To address safety concerns raised in the FDA's approvable letter for Zenvia for the treatment of IEED, the company intends to initiate a confirmatory phase III study with a new lower quinidine dose formulation of Zenvia. The Company is considering whether it would be necessary or advisable to study a similar lower dose of quinidine in the second phase III trial being planned for diabetic neuropathic pain.

About Avanir

Avanir Pharmaceuticals is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. Avanir's products and product candidates address therapeutic markets that include the central nervous system, inflammation and infectious diseases. Avanir currently markets FazaClo(R), the only orally-disintegrating formulation of clozapine for the management of severely ill schizophrenic patients who fail to respond adequately to standard schizophrenic drug treatments. FazaClo is als
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:5/22/2015)...  The Mesothelioma Victims Center is incredibly passionate ... the best possible compensation, and they are also extremely ... cancer caused by exposure to asbestos or their ... treatment options such as a recent possible medical breakthrough. ... Center anytime at 866-714-6466. http://MesotheliomaVictimsCenter.Com ...
(Date:5/22/2015)... , May 22, 2015   InspireMD, Inc. ... stent embolic protection systems ("EPS"), today announced that its CGuard ... lead by principle investigator Prof. Piotr Musialek , at ... Paris, France . PARADIGM, an ... R cutaneous c A roti D revascularization I ...
(Date:5/22/2015)...  In a sweeping analysis assessing the current state ... researchers conclude that there remains considerable room for ... age groups, but especially for adolescents and young adults. ... treatment, underscoring the need to address barriers to care ... type 1 patients achieve optimal metabolic control. ...
Breaking Medicine Technology:Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5
... SAN DIEGO, Feb. 17, 2011 Orexigen® Therapeutics, Inc. (Nasdaq: ... Graham Cooper, senior vice president, Finance, CFO and treasurer. Mr. ... has decided to leave the Company for personal reasons.  He ... accepting the CFO role in 2006.  Mr. Cooper will remain ...
... Feb. 17, 2011 In celebration of the 31st Annual ... NXTM ), a leading manufacturer of innovative dialysis products, today ... System One for home hemodialysis.  The System One is the ... the FDA. "This new milestone demonstrates growing ...
Cached Medicine Technology:Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer 2Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer 3In Celebration of the 31st Annual Dialysis Conference, NxStage® Announces Over 5,000 Patients Using the System One™ for Home Hemodialysis 2In Celebration of the 31st Annual Dialysis Conference, NxStage® Announces Over 5,000 Patients Using the System One™ for Home Hemodialysis 3
(Date:5/24/2015)... New York, New York (PRWEB) May 24, 2015 ... of testosterone treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) has ... discuss the progress of the multidistrict litigation. According ... Court, Northern District of Illinois, the Conference will ... p.m. (In re: Testosterone Replacement Therapy Product Liability ...
(Date:5/24/2015)... Medicx Media Solutions http://www.medicxmedia.com ... Jay Krihak as its head of programmatic strategy ... its expertise and leadership position in the data ... sectors. , Krihak is an experienced, award-winning agency ... led sales planning teams for mobile platform Jumptap. ...
(Date:5/23/2015)... 2015 On Saturday, May 23, 2015, over ... for Branches Florida City exactly five years to the day ... 2010. , A large fire tore through the Branches United ... 2010 in the middle of the night as neighbors, staff ... declared arson even though it is suspected that the fire ...
(Date:5/23/2015)... San Diego, CA (PRWEB) May 23, 2015 ... businesses, especially small businesses, are finding it increasingly difficult ... Those businesses which fail to provide adequate insurance for ... healthcare for businesses been such an integral part of ... provide more affordable healthcare for businesses, Online USA Doctors ...
(Date:5/23/2015)... 23, 2015 Manufacturers are now required to ... (HSPF) of 8.2. Experts in the field agree that the ... , The HSPF score is what miles per gallon is ... the unit. Although the minimum HSPF score has been raised ... an HSPF score north of 12. Indeed, the regulation was ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3Health News:Medicx Media Solutions Expands Executive Team 2Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2
... Oct. 11 SeaView IPA, an Oxnard, CA ... P. Bangasser Memorial,Award for Quality Improvement from the ... a special Awards Ceremony at the 6th,Annual Pay-for-Performance ... The IHA is a statewide leadership group ...
... 2007 Physicians at UT Southwestern Medical Center are the first ... radioactive pellet, or seed, is implanted into a mass or suspicious ... removal. , During the procedure, a radiologist uses a needle to ... of rice, into the mass. Once lodged, surgeons use a wand ...
... to Support Amendment to Hologic,s 1999 Equity ... ... Inc.,(Nasdaq: HOLX ), a leading provider of state-of-the-art diagnostic and,digital ... independent proxy advisory service, recommends that,Hologic stockholders vote "FOR" the Company,s ...
... Brochure Outlines Step-by-Step Process and Provides Sample Appeal,Letter, ... many seniors peace of mind that they will have,access ... individual,plan rules, the medicine that,s prescribed by the doctor ... but they need,to know what they can do about ...
... MEMPHIS, Tenn., Oct. 11 Baptist Memorial Health ... the University of Memphis,today, bringing its recent total ... million. Last month, Baptist contributed $1 million ... to Southwest Tennessee Community,College,s nursing, natural sciences and ...
... allows hospital pharmacies to accurately manage costs and ... ... 11 Omnicell, Inc.,(Nasdaq: OMCL ) a leading provider of ... efficiency, today,announced the Omnicell WorkflowRx 5.0 central pharmacy automation solution.,With its ...
Cached Medicine News:Health News:MED3OOO Client Wins IHA Pay-for-Performance Award 2Health News:MED3OOO Client Wins IHA Pay-for-Performance Award 3Health News:New 'seed' therapy helps pinpoint breast tumors with more accuracy 2Health News:ISS Recommends Hologic Stockholders Vote 'FOR' Merger With Cytyc 2Health News:ISS Recommends Hologic Stockholders Vote 'FOR' Merger With Cytyc 3Health News:ISS Recommends Hologic Stockholders Vote 'FOR' Merger With Cytyc 4Health News:New Resource Explains What Seniors Can Do if Medicare Denies Coverage of Their Medicines 2Health News:Baptist Memorial Health Care Donates More Than $3 Million to Tennessee Universities and Colleges 2Health News:Omnicell Introduces the Next Generation Central Pharmacy Automation Solution 2Health News:Omnicell Introduces the Next Generation Central Pharmacy Automation Solution 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: